King & Wood Mallesons is proud to have advised leading global animal healthcare company Zoetis on its acquisition of Australian-based animal pharmaceutical manufacturer Jurox.
The acquisition of Jurox will deliver Zoetis a valuable animal health portfolio, including leading animal anaesthetic Alfaxan®, and high-quality, local manufacturing operations in Australia as well as additional regional offices and subsidiaries in New Zealand, U.S., Canada and the UK, bolstering Zoetis’ product range and global footprint.
A KWM deal team led by M&A Partner Ros Anderson and Special Counsel Clifford Sandler advised Zoetis on all aspects of the transaction, which involved significant cross practice collaboration.
Partners Sharon Henrick and Patrick Gunning provided competition, IP and regulatory advice. Cross-border and Foreign Investment Review Board regulatory input came from Malcolm Brennan.
Commenting on the deal, KWM Partner Ros Anderson said:
“We’re delighted to have assisted Zoetis in securing this strategic acquisition.”
“Jurox brings Zoetis a high-quality portfolio of products, manufacturing capability and expansion opportunities, and that represents an exciting affirmation for Australia’s biomedical sector - this deal demonstrates the sector’s ability to turn scientific excellence into products which both make a difference and generate significant value commercially.”
Subject to the satisfaction of closing conditions and regulatory requirements, deal completion is expected in the first half of 2022.